-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 10, CSPC issued an announcement stating that the new anti-tumor nano-drug "Sirolimus for injection (albumin-binding)" developed by Sinoqi Pharmaceutical, a subsidiary of the company, had been approved for clinical trials in China
.
CSPC announced that this is the first injection-administered sirolimus preparation that has obtained a clinical trial license in China
Sirolimus, also known as rapamycin, was originally developed by Pfizer
.
The drug is a macrolide antibiotic immunosuppressant, a specific inhibitor of mTOR, and is clinically used to prevent organ rejection in patients undergoing kidney transplantation
It is reported that the clinical research indications approved for the drug this time are solid tumors and hematomas